Benedicte Parm Ulhøi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benedicte Parm Ulhøi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Karina Dalsgaard Sorensen
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
3 shared publications - Maibritt Nørgaard
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
3 shared publications - Marianne Trier Bjerre
Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark
3 shared publications - Michael Borre
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
3 shared publications - Christian Godballe
Department of Oto-Rhino-Laryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark
2 shared publications - Christian von Buchwald
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology Rigshospitalet, University of Copenhagen Copenhagen Denmark
2 shared publications
Latest Publications
- Open Access
- 21 February 2025
- Published by Journal of Biological Methods in Bladder
- Vol. 12 (1) , e21200033
Assessment of lower urinary tract symptoms and their impact on quality of life following radiation therapy for bladder cancer
Background: Radiation therapy is a common treatment modality for muscle-invasive bladder cancer (BC). Unfortunately, approximately 5 – 10% of treated patients suffer from long-term complications, such as radiation cystitis. While radiation cystitis initially causes urinary symptoms, it can progress to chronic late effects over time. This treatment may have significant physical and psychological implications for cancer survivors. Methods: This prospective, observational multicenter study was conducted in Denmark from 2020 to 2023. Male patients undergoing radiation treatment for BC were included and stratified into two groups based on radiation strategy: 64 Gy/32 fractions versus 36 Gy/6 fractions. Patients completed baseline and follow-up questionnaires assessing lower urinary tract symptoms and quality of life (QoL). Results: A total of 26 patients were enrolled into the study, with three patients withdrawing consent. Eleven patients were assigned to the 64 Gy/32 fraction group and 12 to the 36 Gy/6 fraction group. At baseline, patients receiving 64 Gy/32 fraction reported a lower impact on QoL, with a median (interquartile range [IQR]) score of 2 (24) compared to 20 (27) in the 36 Gy/6 fraction group. At the 4-month follow-up, the median (IQR) total QoL score was 25 (27) in the 64 Gy 32 fraction group and 6 (14) in the 36 Gy/6 fraction group. At 12 months, the scores were 16 (35) and 3 (3), respectively. Conclusion: These findings suggest that the total radiation dose has a greater impact on urinary symptoms and QoL than the fractionation strategy. However, due to the low inclusion rate, these findings should be interpreted with caution.
- 21 February 2025
- Published by Journal of Biological Methods in Bladder
- Vol. 12 (1) , e21200033
Open AccessAssessment of lower urinary tract symptoms and their impact on quality of life following radiation therapy for bladder cancer
Background: Radiation therapy is a common treatment modality for muscle-invasive bladder cancer (BC). Unfortunately, approximately 5 – 10% of treated patients suffer from long-term complications, such as radiation cystitis. While radiation cystitis initially causes urinary symptoms, it can progress to chronic late effects over time. This treatment may have significant physical and psychological implications for cancer survivors. Methods: This prospective, observational multicenter study was conducted in Denmark from 2020 to 2023. Male patients undergoing radiation treatment for BC were included and stratified into two groups based on radiation strategy: 64 Gy/32 fractions versus 36 Gy/6 fractions. Patients completed baseline and follow-up questionnaires assessing lower urinary tract symptoms and quality of life (QoL). Results: A total of 26 patients were enrolled into the study, with three patients withdrawing consent. Eleven patients were assigned to the 64 Gy/32 fraction group and 12 to the 36 Gy/6 fraction group. At baseline, patients receiving 64 Gy/32 fraction reported a lower impact on QoL, with a median (interquartile range [IQR]) score of 2 (24) compared to 20 (27) in the 36 Gy/6 fraction group. At the 4-month follow-up, the median (IQR) total QoL score was 25 (27) in the 64 Gy 32 fraction group and 6 (14) in the 36 Gy/6 fraction group. At 12 months, the scores were 16 (35) and 3 (3), respectively. Conclusion: These findings suggest that the total radiation dose has a greater impact on urinary symptoms and QoL than the fractionation strategy. However, due to the low inclusion rate, these findings should be interpreted with caution.
- 28 December 2024
- Published by Elsevier in Oral Oncology
- Vol. 161, 107166
Tongue base mucosectomy: A case for precision
- 28 December 2024
- Published by Elsevier in Oral Oncology
- Vol. 161, 107166
Tongue base mucosectomy: A case for precision
- Open Access
- 30 October 2024
- Published by Elsevier in Oral Oncology
- Vol. 159, 107083
The value of tongue base mucosectomy in the work-up of squamous cell carcinoma of unknown primary: A Danish national cohort study
- 30 October 2024
- Published by Elsevier in Oral Oncology
- Vol. 159, 107083
Open AccessThe value of tongue base mucosectomy in the work-up of squamous cell carcinoma of unknown primary: A Danish national cohort study
- Open Access
Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential
Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to improve diagnosis and risk stratification. Here, we investigated the biomarker potential in localized and de novo metastatic PCa (mPCa) of methylated circulating tumor DNA (ctDNA) in plasma. Using the Marmal-aid database and in-house datasets, we identified three top candidates specifically hypermethylated in PCa tissue: DOCK2, HAPLN3, and FBXO30 (specificity/sensitivity: 80%–100%/75–94%). These candidates were further analyzed in plasma samples from 36 healthy controls, 61 benign prostatic hyperplasia (BPH), 102 localized PCa, and 65 de novo mPCa patients using methylation-specific droplet digital PCR. Methylated ctDNA for DOCK2/HAPLN3/FBXO30 was generally not detected in healthy controls, BPH patients, nor in patients with localized PCa despite a positive signal in 98%–100% of matched radical prostatectomy tissue samples. However, ctDNA methylation of DOCK2, HAPLN3, and/or FBXO30 was detected in 61.5% (40/65) of de novo mPCa patients and markedly increased in high- compared to low-volume mPCa (89.3% (25/28) vs. 32.1% (10/31), p < 0.001). Moreover, detection of methylated ctDNA was associated with significantly shorter time to progression to metastatic castration resistant PCa, independent of tumor-volume. These results indicate that methylated ctDNA (DOCK2/HAPLN3/FBXO30) may be potentially useful for identification of hormone-naïve mPCa patients who could benefit from intensified treatment.
Open AccessEpigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential
Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to improve diagnosis and risk stratification. Here, we investigated the biomarker potential in localized and de novo metastatic PCa (mPCa) of methylated circulating tumor DNA (ctDNA) in plasma. Using the Marmal-aid database and in-house datasets, we identified three top candidates specifically hypermethylated in PCa tissue: DOCK2, HAPLN3, and FBXO30 (specificity/sensitivity: 80%–100%/75–94%). These candidates were further analyzed in plasma samples from 36 healthy controls, 61 benign prostatic hyperplasia (BPH), 102 localized PCa, and 65 de novo mPCa patients using methylation-specific droplet digital PCR. Methylated ctDNA for DOCK2/HAPLN3/FBXO30 was generally not detected in healthy controls, BPH patients, nor in patients with localized PCa despite a positive signal in 98%–100% of matched radical prostatectomy tissue samples. However, ctDNA methylation of DOCK2, HAPLN3, and/or FBXO30 was detected in 61.5% (40/65) of de novo mPCa patients and markedly increased in high- compared to low-volume mPCa (89.3% (25/28) vs. 32.1% (10/31), p < 0.001). Moreover, detection of methylated ctDNA was associated with significantly shorter time to progression to metastatic castration resistant PCa, independent of tumor-volume. These results indicate that methylated ctDNA (DOCK2/HAPLN3/FBXO30) may be potentially useful for identification of hormone-naïve mPCa patients who could benefit from intensified treatment.
- Open Access
- 22 October 2019
- Published by Springer Nature in Clinical Epigenetics
- Vol. 11 (1) , 1-14
Epigenetic silencing of MEIS2 in prostate cancer recurrence
Background: Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed. Results: In this study, we integrated genome-wide methylome (Illumina 450K DNA methylation array (450K)) and RNA sequencing (RNAseq) data performed in a discovery set of 27 PC and 15 adjacent normal (AN) prostate tissue samples to identify candidate driver genes involved in PC development and/or progression. We found significant enrichment for homeobox genes among the most aberrantly methylated and transcriptionally dysregulated genes in PC. Specifically, homeobox gene MEIS2 (Myeloid Ecotropic viral Insertion Site 2) was significantly hypermethylated (p < 0.0001, Mann-Whitney test) and transcriptionally downregulated (p < 0.0001, Mann-Whitney test) in PC compared to non-malignant prostate tissue in our discovery sample set, which was also confirmed in an independent validation set including > 500 PC and AN tissue samples in total (TCGA cohort analyzed by 450K and RNAseq). Furthermore, in three independent radical prostatectomy (RP) cohorts (n > 700 patients in total), low MEIS2 transcriptional expression was significantly associated with poor biochemical recurrence (BCR) free survival (p = 0.0084, 0.0001, and 0.0191, respectively; log-rank test). Next, we analyzed another RP cohort consisting of > 200 PC, AN, and benign prostatic hyperplasia (BPH) samples by quantitative methylation-specific PCR (qMSP) and found that MEIS2 was significantly hypermethylated (p < 0.0001, Mann-Whitney test) in PC compared to non-malignant prostate tissue samples (AN and BPH) with an AUC > 0.84. Moreover, in this cohort, aberrant MEIS2 hypermethylation was significantly associated with post-operative BCR (p = 0.0068, log-rank test), which was subsequently confirmed (p = 0.0067; log-rank test) in the independent TCGA validation cohort (497 RP patients; 450K data). Conclusions: To the best of our knowledge, this is the first study to investigate, demonstrate, and independently validate a prognostic biomarker potential for MEIS2 at the transcriptional expression level and at the DNA methylation level in PC.
- 22 October 2019
- Published by Springer Nature in Clinical Epigenetics
- Vol. 11 (1) , 1-14
Open AccessEpigenetic silencing of MEIS2 in prostate cancer recurrence
Background: Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed. Results: In this study, we integrated genome-wide methylome (Illumina 450K DNA methylation array (450K)) and RNA sequencing (RNAseq) data performed in a discovery set of 27 PC and 15 adjacent normal (AN) prostate tissue samples to identify candidate driver genes involved in PC development and/or progression. We found significant enrichment for homeobox genes among the most aberrantly methylated and transcriptionally dysregulated genes in PC. Specifically, homeobox gene MEIS2 (Myeloid Ecotropic viral Insertion Site 2) was significantly hypermethylated (p < 0.0001, Mann-Whitney test) and transcriptionally downregulated (p < 0.0001, Mann-Whitney test) in PC compared to non-malignant prostate tissue in our discovery sample set, which was also confirmed in an independent validation set including > 500 PC and AN tissue samples in total (TCGA cohort analyzed by 450K and RNAseq). Furthermore, in three independent radical prostatectomy (RP) cohorts (n > 700 patients in total), low MEIS2 transcriptional expression was significantly associated with poor biochemical recurrence (BCR) free survival (p = 0.0084, 0.0001, and 0.0191, respectively; log-rank test). Next, we analyzed another RP cohort consisting of > 200 PC, AN, and benign prostatic hyperplasia (BPH) samples by quantitative methylation-specific PCR (qMSP) and found that MEIS2 was significantly hypermethylated (p < 0.0001, Mann-Whitney test) in PC compared to non-malignant prostate tissue samples (AN and BPH) with an AUC > 0.84. Moreover, in this cohort, aberrant MEIS2 hypermethylation was significantly associated with post-operative BCR (p = 0.0068, log-rank test), which was subsequently confirmed (p = 0.0067; log-rank test) in the independent TCGA validation cohort (497 RP patients; 450K data). Conclusions: To the best of our knowledge, this is the first study to investigate, demonstrate, and independently validate a prognostic biomarker potential for MEIS2 at the transcriptional expression level and at the DNA methylation level in PC.
- Open Access
- 7 March 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (5) , 1173
Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer
Prostate cancer (PCa) is a clinically heterogeneous disease and currently, accurate diagnostic and prognostic molecular biomarkers are lacking. This study aimed to identify novel DNA hypermethylation markers for PCa with future potential for blood-based testing. Accordingly, to search for genes specifically hypermethylated in PCa tissue samples and not in blood cells or other cancer tissue types, we performed a systematic analysis of genome-wide DNA methylation data (Infinium 450K array) available in the Marmal-aid database for 4072 malignant/normal tissue samples of various types. We identified eight top candidate markers (cg12799885, DOCK2, FBXO30, GRASP, HIF3A, MOB3B, PFKP, and TPM4) that were specifically hypermethylated in PCa tissue samples and hypomethylated in other benign and malignant tissue types, including in peripheral blood cells. Potential as diagnostic and prognostic biomarkers was further assessed by the quantitative methylation specific PCR (qMSP) analysis of 37 nonmalignant and 197 PCa tissue samples from an independent population. Here, all eight hypermethylated candidates showed high sensitivity (75–94%) and specificity (84–100%) for PCa. Furthermore, DOCK2, GRASP, HIF3A and PKFP hypermethylation was significantly associated with biochemical recurrence (BCR) after radical prostatectomy (RP; 197 patients), independent of the routine clinicopathological variables. DOCK2 is the most promising single candidate marker (hazard ratio (HR) (95% confidence interval (CI)): 1.96 (1.24–3.10), adjusted p = 0.016; multivariate cox regression). Further validation studies are warranted and should investigate the potential value of these hypermethylation candidate markers for blood-based testing also.
- 7 March 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (5) , 1173
Open AccessAberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer
Prostate cancer (PCa) is a clinically heterogeneous disease and currently, accurate diagnostic and prognostic molecular biomarkers are lacking. This study aimed to identify novel DNA hypermethylation markers for PCa with future potential for blood-based testing. Accordingly, to search for genes specifically hypermethylated in PCa tissue samples and not in blood cells or other cancer tissue types, we performed a systematic analysis of genome-wide DNA methylation data (Infinium 450K array) available in the Marmal-aid database for 4072 malignant/normal tissue samples of various types. We identified eight top candidate markers (cg12799885, DOCK2, FBXO30, GRASP, HIF3A, MOB3B, PFKP, and TPM4) that were specifically hypermethylated in PCa tissue samples and hypomethylated in other benign and malignant tissue types, including in peripheral blood cells. Potential as diagnostic and prognostic biomarkers was further assessed by the quantitative methylation specific PCR (qMSP) analysis of 37 nonmalignant and 197 PCa tissue samples from an independent population. Here, all eight hypermethylated candidates showed high sensitivity (75–94%) and specificity (84–100%) for PCa. Furthermore, DOCK2, GRASP, HIF3A and PKFP hypermethylation was significantly associated with biochemical recurrence (BCR) after radical prostatectomy (RP; 197 patients), independent of the routine clinicopathological variables. DOCK2 is the most promising single candidate marker (hazard ratio (HR) (95% confidence interval (CI)): 1.96 (1.24–3.10), adjusted p = 0.016; multivariate cox regression). Further validation studies are warranted and should investigate the potential value of these hypermethylation candidate markers for blood-based testing also.
- Open Access
- 19 March 2009
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (3) , 1204-1214
Beyond Climate Focus and Disciplinary Myopia. The Roles and Responsibilities of Hospitals and Healthcare Professionals
This paper calls for the need to address climate change within the concept of sustainable development, in recognition of the interrelationships between environmental, economic and social systems. So far, health- providing organizations such as hospitals have paid surprisingly little attention to the relationships between environmental change (e.g. climate change) and human health, or between hospitals (as professional organizations) and their impact on sustainable development. Although it is usually such industries as the chemical, extractive and metal industries, etc., that are associated with environmentally harmful activities, there is also an urgent need to emphasize the roles and responsibilities of hospitals and their embeddedness in a wider ecological, economic and social context. The key objective here is to discuss the relevance of sustainability and environmental management issues in a sector that until now has conveniently ignored its roles and responsibilities in relation to sustainability issues. The paper concludes that arguments based on systems theory, environment, medicine, economics and innovation strongly urge hospitals to reconsider their present roles and environmental responsibilities.
- 19 March 2009
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (3) , 1204-1214
Open AccessBeyond Climate Focus and Disciplinary Myopia. The Roles and Responsibilities of Hospitals and Healthcare Professionals
This paper calls for the need to address climate change within the concept of sustainable development, in recognition of the interrelationships between environmental, economic and social systems. So far, health- providing organizations such as hospitals have paid surprisingly little attention to the relationships between environmental change (e.g. climate change) and human health, or between hospitals (as professional organizations) and their impact on sustainable development. Although it is usually such industries as the chemical, extractive and metal industries, etc., that are associated with environmentally harmful activities, there is also an urgent need to emphasize the roles and responsibilities of hospitals and their embeddedness in a wider ecological, economic and social context. The key objective here is to discuss the relevance of sustainability and environmental management issues in a sector that until now has conveniently ignored its roles and responsibilities in relation to sustainability issues. The paper concludes that arguments based on systems theory, environment, medicine, economics and innovation strongly urge hospitals to reconsider their present roles and environmental responsibilities.